{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:04:16Z","timestamp":1782457456061,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T00:00:00Z","timestamp":1431734400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00262-015-1703-7","type":"journal-article","created":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T06:25:43Z","timestamp":1431671143000},"page":"1021-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study"],"prefix":"10.1007","volume":"64","author":[{"given":"Katy J.","family":"McCann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Godeseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Chudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Di Genova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lloyd-Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir B.","family":"Malykh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim H.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freda K.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Ottensmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,16]]},"reference":[{"key":"1703_CR1","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working Party (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875\u20131883","journal-title":"N Engl J Med"},{"key":"1703_CR2","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","volume":"23","author":"JP Fermand","year":"2005","unstructured":"Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P, Group M-A (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55\u201365\u00a0years: long-term results of a randomized control trial from the group myelome-autogreffe. J Clin Oncol 23:9227\u20139233","journal-title":"J Clin Oncol"},{"key":"1703_CR3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520","journal-title":"Blood"},{"key":"1703_CR4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","volume":"154","author":"JM Bird","year":"2011","unstructured":"Bird JM, Owen RG, D\u2019Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J, Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154:32\u201375","journal-title":"Br J Haematol"},{"key":"1703_CR5","first-page":"209","volume":"7","author":"HN Eisen","year":"1975","unstructured":"Eisen HN, Sakato N, Hall SJ (1975) Myeloma proteins as tumor-specific antigens. Transplant Proc 7:209\u2013214","journal-title":"Transplant Proc"},{"key":"1703_CR6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/08830188909044783","volume":"4","author":"AJ George","year":"1989","unstructured":"George AJ, Stevenson FK (1989) Prospects for the treatment of B cell tumors using idiotypic vaccination. Int Rev Immunol 4:271\u2013310","journal-title":"Int Rev Immunol"},{"key":"1703_CR7","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/3266","volume":"4","author":"CA King","year":"1998","unstructured":"King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4:1281\u20131286","journal-title":"Nat Med"},{"key":"1703_CR8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/01.cji.0000171312.16171.77","volume":"28","author":"S Cohen","year":"2005","unstructured":"Cohen S, Haimovich J, Hollander N (2005) B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. J Immunother 28:461\u2013466","journal-title":"J Immunother"},{"key":"1703_CR9","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jnci\/djj358","volume":"98","author":"S Inoges","year":"2006","unstructured":"Inoges S, Rodriguez-Calvillo M, Zabalegui N, Lopez-Diaz de Cerio A, Villanueva H, Soria E, Suarez L, Rodriguez-Caballero A, Pastor F, Garcia-Munoz R, Panizo C, Perez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M, Espanol Grupo, de Linfomas Trasplante, de Medula Autologo, Grupo Espa\u00f1ol de Linfomas\/Trasplante Autologo de Medula Oseo study group, Programa para el Estudio y Tratamiento de Hemopatias Malignas study group (2006) Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 98:1292\u20131301","journal-title":"J Natl Cancer Inst"},{"key":"1703_CR10","first-page":"941","volume":"91","author":"B Bogen","year":"2006","unstructured":"Bogen B, Ruffini PA, Corthay A, Fredriksen AB, Froyland M, Lundin K, Rosjo E, Thompson K, Massaia M (2006) Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica 91:941\u2013948","journal-title":"Haematologica"},{"key":"1703_CR11","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","volume":"89","author":"FJ Hsu","year":"1997","unstructured":"Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2013long-term results of a clinical trial. Blood 89:3129\u20133135","journal-title":"Blood"},{"key":"1703_CR12","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","volume":"29","author":"SJ Schuster","year":"2011","unstructured":"Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW (2011) Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29:2787\u20132794","journal-title":"J Clin Oncol"},{"key":"1703_CR13","first-page":"460","volume":"81","author":"M Ocqueteau","year":"1996","unstructured":"Ocqueteau M, San Miguel JF, Gonzalez M, Almeida J, Orfao A (1996) Do myelomatous plasma cells really express surface immunoglobulins? Haematologica 81:460\u2013463","journal-title":"Haematologica"},{"key":"1703_CR14","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood.V97.6.1750","volume":"97","author":"YJ Wen","year":"2001","unstructured":"Wen YJ, Barlogie B, Yi Q (2001) Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97:1750\u20131755","journal-title":"Blood"},{"key":"1703_CR15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fimmu.2014.00174","volume":"5","author":"OA Haabeth","year":"2014","unstructured":"Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B (2014) How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol 5:174","journal-title":"Front Immunol"},{"key":"1703_CR16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/1078-0432.CCR-06-2650","volume":"13","author":"F Rhee","year":"2007","unstructured":"Rhee F (2007) Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system. Clin Cancer Res 13:1353\u20131355","journal-title":"Clin Cancer Res"},{"key":"1703_CR17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.leu.2403181","volume":"18","author":"M Coscia","year":"2004","unstructured":"Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M (2004) Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 18:139\u2013145","journal-title":"Leukemia"},{"key":"1703_CR18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1078-0432.CCR-06-1603","volume":"13","author":"L Hansson","year":"2007","unstructured":"Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H (2007) Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 13:1503\u20131510","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 2","key":"1703_CR19","doi-asserted-by":"crossref","first-page":"14646","DOI":"10.1073\/pnas.0404896101","volume":"101","author":"FK Stevenson","year":"2004","unstructured":"Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, Roddick JS, King AT, McNicholl F, Savelyeva N, Rice J (2004) DNA vaccines to attack cancer. Proc Natl Acad Sci USA 101(Suppl. 2):14646\u201314652","journal-title":"Proc Natl Acad Sci USA"},{"key":"1703_CR20","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1182\/blood.V83.11.3279.3279","volume":"83","author":"RE Hawkins","year":"1994","unstructured":"Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, Stevenson FK (1994) Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83:3279\u20133288","journal-title":"Blood"},{"key":"1703_CR21","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.159.4.1885","volume":"159","author":"MB Spellerberg","year":"1997","unstructured":"Spellerberg MB, Zhu D, Thompsett A, King CA, Hamblin TJ, Stevenson FK (1997) DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J Immunol 159:1885\u20131892","journal-title":"J Immunol"},{"key":"1703_CR22","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/eji.1830261119","volume":"26","author":"B Bogen","year":"1996","unstructured":"Bogen B (1996) Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 26:2671\u20132679","journal-title":"Eur J Immunol"},{"key":"1703_CR23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2009.09.007","volume":"31","author":"S Janetzki","year":"2009","unstructured":"Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM (2009) \u201cMIATA\u201d\u2014minimal information about T cell assays. Immunity 31:527\u2013528","journal-title":"Immunity"},{"key":"1703_CR24","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1023\/A:1008375931236","volume":"10","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann Oncol 10:1419\u20131432","journal-title":"Ann Oncol"},{"key":"1703_CR25","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood.V92.5.1471","volume":"92","author":"T Guillaume","year":"1998","unstructured":"Guillaume T, Rubinstein DB, Symann M (1998) Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92:1471\u20131490","journal-title":"Blood"},{"key":"1703_CR26","first-page":"105","volume":"113","author":"SS Sahota","year":"2005","unstructured":"Sahota SS, Townsend M, Stevenson FK (2005) Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma. Methods Mol Med 113:105\u2013119","journal-title":"Methods Mol Med"},{"key":"1703_CR27","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.molimm.2007.10.009","volume":"45","author":"KJ McCann","year":"2008","unstructured":"McCann KJ, Ottensmeier CH, Callard A, Radcliffe CM, Harvey DJ, Dwek RA, Rudd PM, Sutton BJ, Hobby P, Stevenson FK (2008) Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. Mol Immunol 45:1567\u20131572","journal-title":"Mol Immunol"},{"key":"1703_CR28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00262-008-0633-z","volume":"58","author":"A Mander","year":"2009","unstructured":"Mander A, Chowdhury F, Low L, Ottensmeier CH (2009) Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. Cancer Immunol Immunother 58:789\u2013800","journal-title":"Cancer Immunol Immunother"},{"key":"1703_CR29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1086\/367702","volume":"187","author":"ND Russell","year":"2003","unstructured":"Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ (2003) Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 187:226\u2013242","journal-title":"J Infect Dis"},{"key":"1703_CR30","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412\u20133420","journal-title":"J Clin Oncol"},{"key":"1703_CR31","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1345\/aph.1A277","volume":"36","author":"JR Arrowood","year":"2002","unstructured":"Arrowood JR, Hayney MS (2002) Immunization recommendations for adults with cancer. Ann Pharmacother 36:1219\u20131229","journal-title":"Ann Pharmacother"},{"key":"1703_CR32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/B978-012372551-6\/50075-4","volume-title":"Cancer immunotherapy: immune suppression and tumor growth","author":"FK Stevenson","year":"2007","unstructured":"Stevenson FK, Di Genova G, Ottensmeier CH, Savelyeva N (2007) Cancer Vaccines. In: Prendergast GC, Jaffee EM (eds) Cancer immunotherapy: immune suppression and tumor growth, 1st edn. Elsevier, London, pp 183\u2013204","edition":"1"},{"key":"1703_CR33","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","volume":"99","author":"JM Timmerman","year":"2002","unstructured":"Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517\u20131526","journal-title":"Blood"},{"key":"1703_CR34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2007.00962.x","volume":"79","author":"AO Abdalla","year":"2007","unstructured":"Abdalla AO, Hansson L, Eriksson I, Nasman-Glaser B, Mellstedt H, Osterborg A (2007) Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients. Eur J Haematol 79:371\u2013381","journal-title":"Eur J Haematol"},{"key":"1703_CR35","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1054\/bjoc.1999.1088","volume":"82","author":"JD Robertson","year":"2000","unstructured":"Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, Zambon M, Scarffe JH (2000) Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 82:1261\u20131265","journal-title":"Br J Cancer"},{"key":"1703_CR36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/sj.icb.7100153","volume":"86","author":"S Moshitzky","year":"2008","unstructured":"Moshitzky S, Kukulansky T, Haimovich J, Hollander N (2008) Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin. Immunol Cell Biol 86:261\u2013267","journal-title":"Immunol Cell Biol"},{"key":"1703_CR37","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/annonc\/mdn017","volume":"19","author":"AO Abdalla","year":"2008","unstructured":"Abdalla AO, Kokhaei P, Hansson L, Mellstedt H, Osterborg A (2008) Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann Oncol 19:1172\u20131179","journal-title":"Ann Oncol"},{"key":"1703_CR38","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/eji.1830161110","volume":"16","author":"B Bogen","year":"1986","unstructured":"Bogen B, Malissen B, Haas W (1986) Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 16:1373\u20131378","journal-title":"Eur J Immunol"},{"key":"1703_CR39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.1995.tb08902.x","volume":"89","author":"A Osterborg","year":"1995","unstructured":"Osterborg A, Yi Q, Bergenbrant S, Holm G, Lefvert AK, Mellstedt H (1995) Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol 89:110\u2013116","journal-title":"Br J Haematol"},{"key":"1703_CR40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.10095","volume":"92","author":"AO Abdalla","year":"2007","unstructured":"Abdalla AO, Hansson L, Eriksson I, Nasman-Glaser B, Rossmann ED, Rabbani H, Mellstedt H, Osterborg A (2007) Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma\u2014evaluation of T-cell responses by different read-out systems. Haematologica 92:110\u2013114","journal-title":"Haematologica"},{"key":"1703_CR41","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1046\/j.1365-2141.2000.01958.x","volume":"108","author":"S Titzer","year":"2000","unstructured":"Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H (2000) Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 108:805\u2013816","journal-title":"Br J Haematol"},{"key":"1703_CR42","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1158\/1078-0432.CCR-12-1881","volume":"19","author":"NC Munshi","year":"2013","unstructured":"Munshi NC, Anderson KC (2013) New strategies in the treatment of multiple myeloma. Clin Cancer Res 19:3337\u20133344","journal-title":"Clin Cancer Res"},{"key":"1703_CR43","doi-asserted-by":"crossref","first-page":"174378","DOI":"10.1155\/2010\/174378","volume":"2010","author":"D Fioretti","year":"2010","unstructured":"Fioretti D, Iurescia S, Fazio VM, Rinaldi M (2010) DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010:174378","journal-title":"J Biomed Biotechnol"},{"key":"1703_CR44","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omede P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371:895\u2013905","journal-title":"N Engl J Med"},{"key":"1703_CR45","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","volume":"18","author":"K Noonan","year":"2012","unstructured":"Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, Borrello I (2012) Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res 18:1426\u20131434","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-015-1703-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-015-1703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-015-1703-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T15:18:26Z","timestamp":1691680706000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-015-1703-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,16]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["1703"],"URL":"https:\/\/doi.org\/10.1007\/s00262-015-1703-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,16]]}}}